Pierre Fabre snags option on Piqur program in skin cancers by Nick Paul Taylor Wednesday, January 11, 2017 Pierre Fabre has struck a deal to develop dermatological formulations of Piqur Therapeutics’ PI3K/mTOR inhibitor PQR309.
